You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

shingrix_logo

Product menu

Video Center

View reconstitution instructions for SHINGRIX▼

You and your office staff can learn how to administer SHINGRIX▼ step by step.

Can Shingles affect your 50+ patients' DAILY LIFE?

Why Rheumatoid Arthritis Patients are at SERIOUS RISK of Shingles?

Can Diabetic & Hypertensive Patients tolerate Shingles STRIKE?

Shingrix▼ Safety Information9

Contraindications:
Hypersensitivity to the active substances or to any component of the vaccine.

Special warnings and precautions:
As with all injectable vaccines:
- appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine;
- vaccination with Shingrix▼ should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination;
- a protective immune response may not be elicited in all vaccinees.
Do not administer the vaccine intravascularly, intradermally or subcutaneously.
There are no data on the use of Shingrix▼ in pregnant women and the effect on breast-fed infants of administration of Shingrix▼ to their mothers has not been studied.

Adverse reactions:
- Very common (≥1/10): headache, gastrointestinal symptoms (including nausea, vomiting, diarrhoea and/or abdominal pain), myalgia, injection site reactions (such as pain, redness, swelling), fatigue, chills, fever.
- Common (≥1/100 to <1/10): injection site pruritus, malaise.
Please refer to the full prescribing information for further details.

References

  1. Harpaz R, et al. MMWR Recomm Rep. 2008 Jun;57(RR-5):1-30.
  2. Kimberlin DW, et al. N Engl J Med. 2007 Mar;356(13):1338-43.
  3. Tseng HF, et al. J Infect Dis. 2016 Jun;213(12):1872-75.
  4. Chlibek R, et al. Vaccine. 2014 Mar;32(15):1745-53.
  5. Approved prescribing information by SFDA for Shingrix▼.
  6. Lal H, et al. N Engl J Med. 2015 May;372(22):2087-96.
  7. Cunningham AL, et al. N Engl J Med. 2016;375(11):1019-32.
  8. Bharucha T, et al. Hum Vaccin Immunother. Forthcoming 2017. doi: 10.1080/21645515.2017.1317410.
  9. Dendouga N, et al. Vaccine. 2012;30(20):3126-35.
  10. Di Pasquale A, et al. Vaccines. 2015 Jun;3(2):320-43.

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com

For more information, please refer to the prescribing information or contact GSK: P.O Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia.
Telephone: +966 12 653 6666 or via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com
To report the Quality related product complaint/s associated with the use of GSK product/s, please contact us via ksa.productqualitycomplaint@gsk.com

GSK does not recommend, endorse or accept liability for sites controlled by a third party.

Trademarks are owned by or licensed to the GSK group of companies.
©2026 GSK group of companies or its licensor
GlaxoSmithKline, Jeddah, 21544, Kingdom of Saudi Arabia.

PM-SA-SGX-WCNT-240011 Date of preparation: January 2026